SAINTImmunological ancillary study to the clinical trial Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial (SAINT)

  1. Ribes, Marta 1
  2. Cèlia Torres 2
  3. Canyelles, Mar 1
  4. Rubio, Rocío 1
  5. Vidal, Marta 2
  6. Izquierdo, Luis 3
  7. Blanco-Di Matteo, Andrés 4
  8. Pineda, Iñigo 5
  9. Fernandez-Montero, Alejandro 6
  10. Jordan-Iborra, Carlota 4
  11. Carmona-Torre, Francisco 7
  12. R Yuste, José 7
  13. l Pozo, Jose Del 8
  14. Reina, Gabriel 9
  15. Sadaba, Belen 6
  16. Fernández-Alonso, Mirian 9
  17. Santamaria, Pere 10
  18. Carolis, Carlo 11
  19. Aguilar, Ruth 2
  20. Macià, Dídac 12
  21. Chaccour, Carlos 13
  22. Dobaño, Carlota 12
  23. Moncunill, Gemma 12
  1. 1 ISGlobal, Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
  2. 2 ISGlobal, Barcelona, Spain
  3. 3 ISGlobal, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III,Barcelona, Spain
  4. 4 Infectious Diseases Division, Clínica Universidad de Navarra, Pamplona, Spain; Internal Medicine Department, Hospital Universitario de Navarra, Pamplona, Spain.
  5. 5 Infectious Diseases Division, Clínica Universidad de Navarra, Pamplona, Spain
  6. 6 Navarra Center for international Development, Universidad de Navarra, Pamplona, Spain.
  7. 7 Infectious Diseases Division, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  8. 8 Infectious Diseases Division, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Department of Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.
  9. 9 Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Department of Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.
  10. 10 Pathogenesis and Treatment of Autoimmunity Group, Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
  11. 11 Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  12. 12 ISGlobal, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Barcelona, Spain
  13. 13 ISGlobal, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Barcelona, Spain; Department of Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.
Show affiliations +

Editor: CORA.Repositori de Dades de Recerca

Year of publication: 2025

Type: Dataset

Version: 1.0

CC BY-NC-SA 4.0

DOI: 10.34810/DATA2167 lock_openOpen access editor

Abstract

SAINT was clinical Trial that aimed at evaluating the efficacy of a single dose of ivermectin in reducing the transmission of SARS-CoV-2 when administered early after disease onset (72h).<br>The clinical trial found a tendency to lower viral loads, lower IgG titers, a marked reduction of anosmia/hyposmia, and a reduction of cough in the ivermectin treated group.<br>Rainwater foundation funded an ancillary study to evaluate whether ivermectin can immunomodulate COVID-19 response.